|
|
- 2019
Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNAKeywords: Bevacizumab, excision repair cross‐complementation group 1, irinotecan, non‐small cell lung cancer, paclitaxel Abstract: We prospectively evaluated the efficacy and toxicity of a non‐platinum triplet regimen for patients with advanced non‐small cell lung cancer (NSCLC) expected to be platinum‐resistant
|
